Is London's AIM the New Nasdaq? Not Yet.
This article was originally published in Start Up
Executive Summary
Some observers see London's ten-year old junior market for high-growth, small-to-mid-cap companies as, if not a Nasdaq-in-waiting, then certainly the most likely exchange to rival it. But although AIM is attracting growing numbers of overseas companies, some sheltering from Sarbanes-Oxley, liquidity and follow-on financing issues remain. AIM isn't Europe's Nasdaq, not yet.
You may also be interested in...
European IPOs Hold Their Own
The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).
European IPOs Hold Their Own
The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).
Biopharma IPOs Start Swing Back to Nasdaq
The trend of biopharma IPOs eschewing Nasdaq for European and other exchanges reverses modestly in 2006.